Brian Leyland-Jones, M.D., Ph.D.

Associate Vice President for Health Affairs
Director, Winship Cancer Institute
Emory University

Brian Leyland-Jones, MD, PhD, has been appointed associate vice president for Health Affairs and director of Emory University's Winship Cancer Institute. Dr. Leyland-Jones holds biochemistry, medical and doctoral degrees from the University of London. He is a fellow of both the ACP and RCPS of Canada. He received the Cheadle Gold Medal in Medicine for research work with Professor Sir William S. Peart. Following house staff training at Hammersmith, Brompton, St. Bartholomew's and London hospitals, he completed both Clinical Pharmacology and Medical Oncology fellowships at Cornell University and Memorial Sloan-Kettering Cancer Center respectively. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a prime interest in the early clinical evaluation of new anti-cancer compounds. In 1983, he moved to the U.S. National Cancer Institute to head the Developmental Chemotherapy section. During this time, he was responsible for the overall development of approximately seventy cytotoxic compounds in various stages of transition from in-vitro screening to Phase III trials.

From January 1990 - May 2000, he served as Founding Chairman of Oncology at McGill University. In this capacity, he has endowed a clinical trails operation that integrated clinical research with five clinical cooperative groups together with over 40 pharmaceutical companies, built completely new sections of Epidemiology and Cancer Pharmacology, tripled its research space and worked with the community to establish eight endowed chairs and several fellowships within the department. The department now encompasses all educational research and clinical components of an integrated comprehensive cancer centre. His main research interests are (1) pharmacodynamics, pharmacokinetics and pharmacogenetics in oncological clinical trials, (2) translation of preclinical models into the clinic; biomarker endpoints in Phase I/II clinical trials and (3) screening and mechanistic studies of novel targeted and chemotherapeutic anticancer agents. Dr Leyland-Jones has authored more than 125 peer-reviewed articles and book contributions, 150 abstracts and 29 patents.

Related Links: